HC Wainwright Reiterates Buy Rating for Viracta Therapeutics (NASDAQ:VIRX)

Viracta Therapeutics (NASDAQ:VIRX – Get Rating)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They presently have a $35.00 target price on the stock.

Separately, Royal Bank of Canada reiterated an “outperform” rating and set a $8.00 price target on shares of Viracta Therapeutics in a research note on Tuesday.

Viracta Therapeutics Trading Down 3.4 %

VIRX opened at $1.69 on Tuesday. Viracta Therapeutics has a 12 month low of $1.21 and a 12 month high of $5.75. The stock has a fifty day moving average price of $1.91 and a 200-day moving average price of $2.83. The company has a current ratio of 8.49, a quick ratio of 8.49 and a debt-to-equity ratio of 0.08. The firm has a market cap of $64.56 million, a price-to-earnings ratio of -1.26 and a beta of 1.33.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of VIRX. Virtu Financial LLC purchased a new stake in shares of Viracta Therapeutics during the fourth quarter worth approximately $29,000. Jane Street Group LLC purchased a new stake in Viracta Therapeutics during the fourth quarter worth about $35,000. Cubist Systematic Strategies LLC purchased a new stake in Viracta Therapeutics during the second quarter worth about $52,000. Two Sigma Investments LP purchased a new stake in Viracta Therapeutics during the fourth quarter worth about $87,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Viracta Therapeutics by 45.8% in the fourth quarter. Renaissance Technologies LLC now owns 139,787 shares of the company’s stock valued at $204,000 after purchasing an additional 43,888 shares in the last quarter. Institutional investors and hedge funds own 32.35% of the company’s stock.

Viracta Therapeutics Company Profile

(Get Rating)

Viracta Therapeutics, Inc a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas.